November 23, 2016 - By Ruchi Gupta · 0 Comments
The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) registered a decrease of 23.93% in short interest. ABUS’s total short interest was 1.14M shares in November as published by FINRA. Its down 23.93% from 1.50 million shares, reported previously. With 105,200 shares average volume, it will take short sellers 11 days to cover their ABUS’s short positions. The short interest to Arbutus Biopharma Corporation’s float is 3.3%. The stock closed at $2.7 during the last session. It is down 46.53% since April 21, 2016 and is downtrending. It has underperformed by 51.86% the S&P500.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has a market cap of $148.07 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.
Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Arbutus Biopharma has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. The rating was initiated by Wedbush on Friday, August 7 with “Outperform”. The rating was upgraded by Chardan Capital Markets on Thursday, June 16 to “Neutral”. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) has “Neutral” rating given on Friday, October 14 by Chardan Capital Markets. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) earned “Mkt Outperform” rating by JMP Securities on Wednesday, September 2. The company was downgraded on Friday, August 5 by Leerink Swann. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) earned “Outperform” rating by Wedbush on Friday, August 7. The rating was downgraded by Chardan Capital Markets to “Sell” on Friday, July 8. Chardan Capital Markets initiated the stock with “Sell” rating in Monday, May 16 report.
More news for Arbutus Biopharma Corp (NASDAQ:ABUS) were recently published by: Marketwatch.com, which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on December 29, 2013. Seekingalpha.com‘s article titled: “Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race” and published on November 17, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta